Retatrutide Regulatory Status Retatrutide occupies a unique position because it is not yet FDA-approved: Not FDA-approved currently in Phase 3 clinical trials with Eli Lilly No prescription pathway in the US yet no Mounjaro/Wegovy equivalent for retatrutide Legal as research chemical sold in the US for in-vitro and animal research under research-use-only labeling Likely to receive FDA approval in coming years if clinical trial endpoints meet expectations WADA status currently not specifically listed, though peptide hormones generally fall under WADA categories Not DEA-scheduled no controlled substance status Unlike semaglutide and tirzepatide, retatrutide does not yet exist as a prescription drug
The genetics of disulfide bond metabolism
Journal reference: Wang, W., Volkow, N.D., Berger, N.A., Davis, P.B., Kaelber, D.C., and Xu, R
The overall cardiovascular risk profile improves meaningfully
By binding to receptors in the hypothalamus, the medication acts on your central nervous system to quiet these urges
How our patients rate their experience in clinic *Data gathered via our post-treatment survey Poor Average Excellent What we do Conditions treated with Vitamin B12 injections Deficiency of Vitamin B12 caused by pernicious anaemia, ageing, or diet (vegan, strict vegetarian, or restricted) which lacks supplementation
